COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
Daniel Junker, Alex Dulovic, View ORCID ProfileMatthias Becker, View ORCID ProfileTeresa R. Wagner, Philipp D. Kaiser, Bjoern Traenkle, Katharina Kienzle, Stefanie Bunk, Carlotta Struemper, Helene Haeberle, Kristina Schmauder, Natalia Ruetalo, Nisar Malek, Karina Althaus, Michael Koeppen, Ulrich Rothbauer, Juliane S. Walz, Michael Schindler, Michael Bitzer, Siri Göpel, View ORCID ProfileNicole Schneiderhan-Marra
doi: https://doi.org/10.1101/2021.08.20.21262328
Daniel Junker
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
Alex Dulovic
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
Matthias Becker
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
Teresa R. Wagner
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
2Pharmaceutical Biotechnology, Eberhard Karls University, Tübingen, Germany
Philipp D. Kaiser
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
Bjoern Traenkle
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
Katharina Kienzle
3Department Internal Medicine I, University Hospital Tübingen, Tübingen, Germany
Stefanie Bunk
3Department Internal Medicine I, University Hospital Tübingen, Tübingen, Germany
Carlotta Struemper
3Department Internal Medicine I, University Hospital Tübingen, Tübingen, Germany
Helene Haeberle
3Department Internal Medicine I, University Hospital Tübingen, Tübingen, Germany
Kristina Schmauder
4Institute for Medical Microbiology and Hygiene, University Hospital Tübingen, Tübingen, Germany
5German Centre for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany
Natalia Ruetalo
6Institute for Medical Virology and Epidemiology, University Hospital Tübingen, Tübingen, Germany
Nisar Malek
3Department Internal Medicine I, University Hospital Tübingen, Tübingen, Germany
7Center for Personalized Medicine, Eberhard Karls University, Tübingen, Germany
Karina Althaus
8Institute for Clinical and Experimental Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany
Michael Koeppen
9Department of Anesthesiology and Intensive Care Medicine, University Hospital Tübingen, Tübingen, Germany
Ulrich Rothbauer
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
2Pharmaceutical Biotechnology, Eberhard Karls University, Tübingen, Germany
Juliane S. Walz
10Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany
11Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany
12Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen, Tübingen, Germany
13Dr. Margarete Fischer-Bosch-Institute for Clinical Pharmacology and Robert Bosch Center for Tumor Diseases (RBCT), Stuttgart, Germany
Michael Schindler
6Institute for Medical Virology and Epidemiology, University Hospital Tübingen, Tübingen, Germany
Michael Bitzer
3Department Internal Medicine I, University Hospital Tübingen, Tübingen, Germany
7Center for Personalized Medicine, Eberhard Karls University, Tübingen, Germany
Siri Göpel
3Department Internal Medicine I, University Hospital Tübingen, Tübingen, Germany
5German Centre for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany
Nicole Schneiderhan-Marra
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
Data Availability
All data generated in this manuscript is available from the authors upon request.
Posted December 06, 2021.
COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
Daniel Junker, Alex Dulovic, Matthias Becker, Teresa R. Wagner, Philipp D. Kaiser, Bjoern Traenkle, Katharina Kienzle, Stefanie Bunk, Carlotta Struemper, Helene Haeberle, Kristina Schmauder, Natalia Ruetalo, Nisar Malek, Karina Althaus, Michael Koeppen, Ulrich Rothbauer, Juliane S. Walz, Michael Schindler, Michael Bitzer, Siri Göpel, Nicole Schneiderhan-Marra
medRxiv 2021.08.20.21262328; doi: https://doi.org/10.1101/2021.08.20.21262328
COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
Daniel Junker, Alex Dulovic, Matthias Becker, Teresa R. Wagner, Philipp D. Kaiser, Bjoern Traenkle, Katharina Kienzle, Stefanie Bunk, Carlotta Struemper, Helene Haeberle, Kristina Schmauder, Natalia Ruetalo, Nisar Malek, Karina Althaus, Michael Koeppen, Ulrich Rothbauer, Juliane S. Walz, Michael Schindler, Michael Bitzer, Siri Göpel, Nicole Schneiderhan-Marra
medRxiv 2021.08.20.21262328; doi: https://doi.org/10.1101/2021.08.20.21262328
Subject Area
Subject Areas
- Addiction Medicine (376)
- Allergy and Immunology (690)
- Anesthesia (185)
- Cardiovascular Medicine (2780)
- Dermatology (237)
- Emergency Medicine (418)
- Epidemiology (12430)
- Forensic Medicine (10)
- Gastroenterology (787)
- Genetic and Genomic Medicine (4297)
- Geriatric Medicine (397)
- Health Economics (705)
- Health Informatics (2776)
- Health Policy (1029)
- Hematology (371)
- HIV/AIDS (882)
- Medical Education (406)
- Medical Ethics (113)
- Nephrology (455)
- Neurology (4072)
- Nursing (218)
- Nutrition (603)
- Oncology (2150)
- Ophthalmology (608)
- Orthopedics (252)
- Otolaryngology (313)
- Pain Medicine (257)
- Palliative Medicine (79)
- Pathology (480)
- Pediatrics (1152)
- Primary Care Research (473)
- Public and Global Health (6677)
- Radiology and Imaging (1457)
- Respiratory Medicine (889)
- Rheumatology (425)
- Sports Medicine (354)
- Surgery (467)
- Toxicology (57)
- Transplantation (194)
- Urology (172)